GeneOne Life Science, Inc. engages in the research, development, and manufacture of deoxyribonucleic acid (DNA) vaccines for the prevention and treatment of diseases. Its products include VGX-3400, VGX-3500, and fluprime. Its service include process cost analysis, sterility testing, research batch production, strain selection, cell bank characterization, and others. It also conduct pre-clinical trials for the treatment of hepatitis C. In addition, it is involved in the contract manufacturing activities for pre-clinical and clinical trials for companies and institutions. The company was founded on January 27, 1976 and is headquartered in Seoul, South Korea.